A Silicon Valley company being closely watched in the race to develop liquid biopsies said Wednesday that it was launching a large clinical trial — one it hopes will support a premarket approval submission for a test for colon cancer.
Guardant Health said it will use its LUNAR test to try to find mutations in tumors that have already been diagnosed. Its study will include 10,000 patients between the ages of 45 and 84 who are at average risk of colon cancer who are going to get a colonoscopy. They will also receive Guardant’s blood test, which will allow researchers to see if they have colon cancer or pre-cancerous polyps.
Details of the trial were posted to ClinicalTrials.gov, a government website that makes information on clinical trials available.